Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan dosing strategies for gastroesophageal reflux disease (GERD)
ChiCTR2300069857Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Union Hospital. Primary endpoints: Symptom relief rate and Esophageal mucosal healing rate. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR2300069857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069857.